Until 8 p.m. includes Twin Cities area

MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all. 

Turn Up Your Support

The Food and Drug Administration approved 

 to treat patients with Alzheimer's disease Monday morning. It is the first new drug approved by the agency for Alzheimer's disease since 2003. 

The drug is the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer's disease. 

The drug has proved highly effective at reducing the plaques, called beta amyloid, that build up in the brains of people with Alzheimer's. 

But two large studies offered conflicting evidence about whether the treatment slows declines in memory and thinking. A panel of expert advisers to the FDA 

As a condition of approval, the FDA is requiring Biogen, the drug's maker, to conduct another clinical study to confirm that the reduction of amyloid plaques results in clinical improvement for patients. If the subsequent study doesn't show a clinical improvement, the agency could move to withdraw the approval.

The medicine will be marketed under the trade name Aduhelm.

Patients will receive the drug in monthly infusions. They will also need regular brain scans to detect a rare side effect: bleeding or swelling in the brain.

Biogen and Eisai, the companies marketing the drug, have yet to announce how much it will cost. 

Science

Health

Scott Hensley

Author

Jon Hamilton

This is the first new drug approved for Alzheimer's disease since 2003. It's the first to show significant progress against the sticky brain plaques that are the hallmark of Alzheimer's disease.

FDA has approved a controversial Alzheimer's drug

Go Deeper.

Like this?

News you can use in your inbox